Characterization and extending the use of the humanized mouse model for psoriasis for pre-clinical testing of new drug.

Characterization and extending the use of the humanized mouse model for psoriasis for pre-clinical testing of new drug. - Expanding knowledge on psoriatic process in the humanized mouse model

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON34915

Enrollment

Registered

2010-03-22

Start date

2010-09-22

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

flaking disease psoriasis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Psoriasis patients: Adults (m/f) with a mild form of psoriasis vulgaris (PASI score of maximal 6). Patients are allowed to use localcorticosteriods or ointments to prevent dry skin (see appendix 2).;Healthy controls: Adults (m/f) who do not have skin condition (as recognized by physisian or dermatologist)

Exclusion criteria

Exclusion criteria: Psoriasis patients: These patients have not received light therapy or another form of systemic treatment (methotrexaat, cyclosporin A,anti-TNF treatments). Gender or age of the adults are not a exclusion criteria.(see appendix 2);Healthy controls: are not to undergo treatment with drugs like prednisolon and cyclosporine.

Design outcomes

Primary

Measure	Time frame
Effect on the psoriatic process is tested by histology and immuno-histochemical techniques in the transplanted biopsies. Main read-out epidermal thickness.	—

Secondary

Measure	Time frame
Additionally, several markers which are know to be associated with lesional psoriasis skin wil be evaluated. This allows us to make a better comparison between the human situation and the processes seen in the model.	—

Countries

Netherlands

Outcome results